Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease

Dominantly Inherited Alzheimer Network

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Owing to an early and marked deposition of amyloid-β in the basal ganglia, autosomal dominant Alzheimer's disease could distinctly involve motor symptoms. Therefore, we aimed to assess the prevalence and characteristics of motor signs in autosomal dominant Alzheimer's disease. Baseline Unified Parkinson Disease Rating Scale part three scores (UPDRS-III) from 433 participants of the Dominantly Inherited Alzheimer's Network observational study were analysed. Motor symptoms were scrutinized with respect to associations with mutation carrier status, mutation site within PSEN1, basal ganglia amyloid-β as measured by Pittsburgh compound B PET, estimated years to symptom onset and Clinical Dementia Rating Scale-Sum of Boxes. Motor findings in mutation carriers were compared to patients with sporadic Alzheimer's disease using data of the National Alzheimer's Coordination Center. Mutation carriers showed motor findings at a higher frequency (28.4% versus 12.8%; P < 0.001) and severity (mean UPDRS-III scores 2.0 versus 0.4; P < 0.001) compared to non-carriers. Eleven of the 27 UPDRS-III items were statistically more frequently affected in mutation carriers after adjustment for multiple comparisons. Ten of these 11 items were subscale components of bradykinesia. In cognitively asymptomatic mutation carriers, dysdiadochokinesia was more frequent compared to non-carriers (right hand: 3.8% versus 0%; adjusted P = 0.023; left: 4.4% versus 0.6%; adjusted P = 0.031). In this cohort, the positive predictive value for mutation carrier status in cognitively asymptomatic participants (50% a priori risk) of dysdiadochokinesia was 100% for the right and 87.5% for the left side. Mutation carriers with motor findings more frequently were basal ganglia amyloid-β positive (84% versus 63.3%; P = 0.006) and showed more basal ganglia amyloid-β deposition (Pittsburgh compound B-standardized uptake value ratio 2.472 versus 1.928; P = 0.002) than those without. Frequency and severity of motor findings were greater in post-codon 200 PSEN1 mutations (36%; mean UPDRS-III score 3.03) compared to mutations pre-codon 200 PSEN1 (19.3%, P = 0.022; 0.91, P = 0.013). In mutation carriers, motor symptom severity was significantly positively correlated with basal ganglia amyloid-β deposition, Clinical Dementia Rating scores and estimated years to symptom onset. Mutation carriers with a Clinical Dementia Rating global score of 2 exhibited more pronounced motor symptoms than sporadic Alzheimer's disease patients with the same Clinical Dementia Rating global score (mean UPDRS-III scores 20.71 versus 5.96; P < 0.001). With a prevalence of approximately 30% and increasing severity with progression of dementia, motor symptoms are proven as a clinically relevant finding in autosomal dominant Alzheimer's disease, in particular in advanced dementia stages, that correlates with deposition of amyloid-β in the basal ganglia. In a very small per cent of cognitively asymptomatic members of families with autosomal dominant Alzheimer's disease, dysdiadochokinesia may increase the chance of an individual's status as mutation carrier.

Original languageEnglish (US)
Pages (from-to)1429-1440
Number of pages12
JournalBrain : a journal of neurology
Volume142
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Alzheimer Disease
Mutation
Basal Ganglia
Amyloid
Dementia
Codon
Hypokinesia
Observational Studies
Parkinson Disease
Hand

Keywords

  • Alzheimer’s disease
  • amyloid-β
  • genetics
  • motor symptoms
  • Unified Parkinson Disease Rating Scale

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. / Dominantly Inherited Alzheimer Network.

In: Brain : a journal of neurology, Vol. 142, No. 5, 01.05.2019, p. 1429-1440.

Research output: Contribution to journalArticle

@article{a10357de978c405f9da05c606c6cdff5,
title = "Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease",
abstract = "Owing to an early and marked deposition of amyloid-β in the basal ganglia, autosomal dominant Alzheimer's disease could distinctly involve motor symptoms. Therefore, we aimed to assess the prevalence and characteristics of motor signs in autosomal dominant Alzheimer's disease. Baseline Unified Parkinson Disease Rating Scale part three scores (UPDRS-III) from 433 participants of the Dominantly Inherited Alzheimer's Network observational study were analysed. Motor symptoms were scrutinized with respect to associations with mutation carrier status, mutation site within PSEN1, basal ganglia amyloid-β as measured by Pittsburgh compound B PET, estimated years to symptom onset and Clinical Dementia Rating Scale-Sum of Boxes. Motor findings in mutation carriers were compared to patients with sporadic Alzheimer's disease using data of the National Alzheimer's Coordination Center. Mutation carriers showed motor findings at a higher frequency (28.4{\%} versus 12.8{\%}; P < 0.001) and severity (mean UPDRS-III scores 2.0 versus 0.4; P < 0.001) compared to non-carriers. Eleven of the 27 UPDRS-III items were statistically more frequently affected in mutation carriers after adjustment for multiple comparisons. Ten of these 11 items were subscale components of bradykinesia. In cognitively asymptomatic mutation carriers, dysdiadochokinesia was more frequent compared to non-carriers (right hand: 3.8{\%} versus 0{\%}; adjusted P = 0.023; left: 4.4{\%} versus 0.6{\%}; adjusted P = 0.031). In this cohort, the positive predictive value for mutation carrier status in cognitively asymptomatic participants (50{\%} a priori risk) of dysdiadochokinesia was 100{\%} for the right and 87.5{\%} for the left side. Mutation carriers with motor findings more frequently were basal ganglia amyloid-β positive (84{\%} versus 63.3{\%}; P = 0.006) and showed more basal ganglia amyloid-β deposition (Pittsburgh compound B-standardized uptake value ratio 2.472 versus 1.928; P = 0.002) than those without. Frequency and severity of motor findings were greater in post-codon 200 PSEN1 mutations (36{\%}; mean UPDRS-III score 3.03) compared to mutations pre-codon 200 PSEN1 (19.3{\%}, P = 0.022; 0.91, P = 0.013). In mutation carriers, motor symptom severity was significantly positively correlated with basal ganglia amyloid-β deposition, Clinical Dementia Rating scores and estimated years to symptom onset. Mutation carriers with a Clinical Dementia Rating global score of 2 exhibited more pronounced motor symptoms than sporadic Alzheimer's disease patients with the same Clinical Dementia Rating global score (mean UPDRS-III scores 20.71 versus 5.96; P < 0.001). With a prevalence of approximately 30{\%} and increasing severity with progression of dementia, motor symptoms are proven as a clinically relevant finding in autosomal dominant Alzheimer's disease, in particular in advanced dementia stages, that correlates with deposition of amyloid-β in the basal ganglia. In a very small per cent of cognitively asymptomatic members of families with autosomal dominant Alzheimer's disease, dysdiadochokinesia may increase the chance of an individual's status as mutation carrier.",
keywords = "Alzheimer’s disease, amyloid-β, genetics, motor symptoms, Unified Parkinson Disease Rating Scale",
author = "{Dominantly Inherited Alzheimer Network} and Jonathan V{\"o}glein and Katrina Paumier and Mathias Jucker and Oliver Preische and Eric McDade and Jason Hassenstab and Benzinger, {Tammie L.} and Noble, {James M.} and Berman, {Sarah B.} and Graff-Radford, {Neill R.} and Bernardino Ghetti and Martin Farlow and Jasmeer Chhatwal and Stephen Salloway and Chengjie Xiong and Karch, {Celeste M.} and Nigel Cairns and Hiroshi Mori and Schofield, {Peter R.} and Masters, {Colin L.} and Alison Goate and Virginia Buckles and Nick Fox and Martin Rossor and Patricio Chrem and Ricardo Allegri and Ringman, {John M.} and G{\"u}nter H{\"o}glinger and Harald Steiner and Marianne Dieterich and Christian Haass and Christoph Laske and Morris, {John C.} and Bateman, {Randall J.} and Adrian Danek and Johannes Levin",
year = "2019",
month = "5",
day = "1",
doi = "10.1093/brain/awz050",
language = "English (US)",
volume = "142",
pages = "1429--1440",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease

AU - Dominantly Inherited Alzheimer Network

AU - Vöglein, Jonathan

AU - Paumier, Katrina

AU - Jucker, Mathias

AU - Preische, Oliver

AU - McDade, Eric

AU - Hassenstab, Jason

AU - Benzinger, Tammie L.

AU - Noble, James M.

AU - Berman, Sarah B.

AU - Graff-Radford, Neill R.

AU - Ghetti, Bernardino

AU - Farlow, Martin

AU - Chhatwal, Jasmeer

AU - Salloway, Stephen

AU - Xiong, Chengjie

AU - Karch, Celeste M.

AU - Cairns, Nigel

AU - Mori, Hiroshi

AU - Schofield, Peter R.

AU - Masters, Colin L.

AU - Goate, Alison

AU - Buckles, Virginia

AU - Fox, Nick

AU - Rossor, Martin

AU - Chrem, Patricio

AU - Allegri, Ricardo

AU - Ringman, John M.

AU - Höglinger, Günter

AU - Steiner, Harald

AU - Dieterich, Marianne

AU - Haass, Christian

AU - Laske, Christoph

AU - Morris, John C.

AU - Bateman, Randall J.

AU - Danek, Adrian

AU - Levin, Johannes

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Owing to an early and marked deposition of amyloid-β in the basal ganglia, autosomal dominant Alzheimer's disease could distinctly involve motor symptoms. Therefore, we aimed to assess the prevalence and characteristics of motor signs in autosomal dominant Alzheimer's disease. Baseline Unified Parkinson Disease Rating Scale part three scores (UPDRS-III) from 433 participants of the Dominantly Inherited Alzheimer's Network observational study were analysed. Motor symptoms were scrutinized with respect to associations with mutation carrier status, mutation site within PSEN1, basal ganglia amyloid-β as measured by Pittsburgh compound B PET, estimated years to symptom onset and Clinical Dementia Rating Scale-Sum of Boxes. Motor findings in mutation carriers were compared to patients with sporadic Alzheimer's disease using data of the National Alzheimer's Coordination Center. Mutation carriers showed motor findings at a higher frequency (28.4% versus 12.8%; P < 0.001) and severity (mean UPDRS-III scores 2.0 versus 0.4; P < 0.001) compared to non-carriers. Eleven of the 27 UPDRS-III items were statistically more frequently affected in mutation carriers after adjustment for multiple comparisons. Ten of these 11 items were subscale components of bradykinesia. In cognitively asymptomatic mutation carriers, dysdiadochokinesia was more frequent compared to non-carriers (right hand: 3.8% versus 0%; adjusted P = 0.023; left: 4.4% versus 0.6%; adjusted P = 0.031). In this cohort, the positive predictive value for mutation carrier status in cognitively asymptomatic participants (50% a priori risk) of dysdiadochokinesia was 100% for the right and 87.5% for the left side. Mutation carriers with motor findings more frequently were basal ganglia amyloid-β positive (84% versus 63.3%; P = 0.006) and showed more basal ganglia amyloid-β deposition (Pittsburgh compound B-standardized uptake value ratio 2.472 versus 1.928; P = 0.002) than those without. Frequency and severity of motor findings were greater in post-codon 200 PSEN1 mutations (36%; mean UPDRS-III score 3.03) compared to mutations pre-codon 200 PSEN1 (19.3%, P = 0.022; 0.91, P = 0.013). In mutation carriers, motor symptom severity was significantly positively correlated with basal ganglia amyloid-β deposition, Clinical Dementia Rating scores and estimated years to symptom onset. Mutation carriers with a Clinical Dementia Rating global score of 2 exhibited more pronounced motor symptoms than sporadic Alzheimer's disease patients with the same Clinical Dementia Rating global score (mean UPDRS-III scores 20.71 versus 5.96; P < 0.001). With a prevalence of approximately 30% and increasing severity with progression of dementia, motor symptoms are proven as a clinically relevant finding in autosomal dominant Alzheimer's disease, in particular in advanced dementia stages, that correlates with deposition of amyloid-β in the basal ganglia. In a very small per cent of cognitively asymptomatic members of families with autosomal dominant Alzheimer's disease, dysdiadochokinesia may increase the chance of an individual's status as mutation carrier.

AB - Owing to an early and marked deposition of amyloid-β in the basal ganglia, autosomal dominant Alzheimer's disease could distinctly involve motor symptoms. Therefore, we aimed to assess the prevalence and characteristics of motor signs in autosomal dominant Alzheimer's disease. Baseline Unified Parkinson Disease Rating Scale part three scores (UPDRS-III) from 433 participants of the Dominantly Inherited Alzheimer's Network observational study were analysed. Motor symptoms were scrutinized with respect to associations with mutation carrier status, mutation site within PSEN1, basal ganglia amyloid-β as measured by Pittsburgh compound B PET, estimated years to symptom onset and Clinical Dementia Rating Scale-Sum of Boxes. Motor findings in mutation carriers were compared to patients with sporadic Alzheimer's disease using data of the National Alzheimer's Coordination Center. Mutation carriers showed motor findings at a higher frequency (28.4% versus 12.8%; P < 0.001) and severity (mean UPDRS-III scores 2.0 versus 0.4; P < 0.001) compared to non-carriers. Eleven of the 27 UPDRS-III items were statistically more frequently affected in mutation carriers after adjustment for multiple comparisons. Ten of these 11 items were subscale components of bradykinesia. In cognitively asymptomatic mutation carriers, dysdiadochokinesia was more frequent compared to non-carriers (right hand: 3.8% versus 0%; adjusted P = 0.023; left: 4.4% versus 0.6%; adjusted P = 0.031). In this cohort, the positive predictive value for mutation carrier status in cognitively asymptomatic participants (50% a priori risk) of dysdiadochokinesia was 100% for the right and 87.5% for the left side. Mutation carriers with motor findings more frequently were basal ganglia amyloid-β positive (84% versus 63.3%; P = 0.006) and showed more basal ganglia amyloid-β deposition (Pittsburgh compound B-standardized uptake value ratio 2.472 versus 1.928; P = 0.002) than those without. Frequency and severity of motor findings were greater in post-codon 200 PSEN1 mutations (36%; mean UPDRS-III score 3.03) compared to mutations pre-codon 200 PSEN1 (19.3%, P = 0.022; 0.91, P = 0.013). In mutation carriers, motor symptom severity was significantly positively correlated with basal ganglia amyloid-β deposition, Clinical Dementia Rating scores and estimated years to symptom onset. Mutation carriers with a Clinical Dementia Rating global score of 2 exhibited more pronounced motor symptoms than sporadic Alzheimer's disease patients with the same Clinical Dementia Rating global score (mean UPDRS-III scores 20.71 versus 5.96; P < 0.001). With a prevalence of approximately 30% and increasing severity with progression of dementia, motor symptoms are proven as a clinically relevant finding in autosomal dominant Alzheimer's disease, in particular in advanced dementia stages, that correlates with deposition of amyloid-β in the basal ganglia. In a very small per cent of cognitively asymptomatic members of families with autosomal dominant Alzheimer's disease, dysdiadochokinesia may increase the chance of an individual's status as mutation carrier.

KW - Alzheimer’s disease

KW - amyloid-β

KW - genetics

KW - motor symptoms

KW - Unified Parkinson Disease Rating Scale

UR - http://www.scopus.com/inward/record.url?scp=85065348568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065348568&partnerID=8YFLogxK

U2 - 10.1093/brain/awz050

DO - 10.1093/brain/awz050

M3 - Article

C2 - 30897203

AN - SCOPUS:85065348568

VL - 142

SP - 1429

EP - 1440

JO - Brain

JF - Brain

SN - 0006-8950

IS - 5

ER -